Literature DB >> 1676268

Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis.

J C Ameisen1, A Capron.   

Abstract

Normal immature thymocytes respond to activation by undergoing programmed cell death (apoptosis), a physiological deletion mechanism involved in the selection of the T-cell repertoire. In this article, Jean Claude Ameisen and André Capron suggest that inappropriate induction of a form of programmed T-cell death could account for both qualitative and quantitative helper T-cell defects of HIV-infected patients. A model of AIDS pathogenesis is presented that may explain several features of HIV infection, including evolution of the disease and the development of defects in nonimmunological organs.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1676268     DOI： 10.1016/0167-5699(91)90092-8

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  106 in total

1.  Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus.

Authors:  Y Sasaki; Y Ami; T Nakasone; K Shinohara; E Takahashi; S Ando; K Someya; Y Suzaki; M Honda
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis.

Authors:  N Johnson; J M Parkin
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 4.  Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease.

Authors:  D Kaplan; S Sieg
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

5.  The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication.

Authors:  M C Re; G Zauli; G Furlini; S Ranieri; P Monari; E Ramazzotti; M La Placa
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Glycosylphosphatidylinositol-anchored CD4 supports human immunodeficiency virus type 1 replication, but not cytopathic effect, in T-cell transfectants.

Authors:  W L Marshall; E S Mittler; P Avery; J P Lawrence; R W Finberg
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.

Authors:  J Trial; H H Birdsall; J A Hallum; M L Crane; M C Rodriguez-Barradas; A L de Jong; B Krishnan; C E Lacke; C G Figdor; R D Rossen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Plasmodium falciparum induces apoptosis in human mononuclear cells.

Authors:  A Toure-Balde; J L Sarthou; G Aribot; P Michel; J F Trape; C Rogier; C Roussilhon
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Impaired proliferative capacity and abnormal cytokine profile of naive and memory CD4 T cells from HIV-seropositive patients.

Authors:  A Cayota; F Vuillier; D Scott-Algara; V Feuillie; G Dighiero
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.